Breakthroughs in the Blood: Leveraging Liquid Biopsy to Improve Cancer Care
Research unveiled at the AACR Annual Meeting 2025 highlighted advances in blood-based liquid biopsy tests to help improve cancer care.
Progress Against Cancer
Research unveiled at the AACR Annual Meeting 2025 highlighted advances in blood-based liquid biopsy tests to help improve cancer care.
Clinical trial results reported at the AACR Annual Meeting 2025 showcased new therapeutic approaches for non-small cell lung cancer.
For April 2025, the editors of AACR's 10 journals highlighted studies on evolution in glioblastoma, new cancer treatment approaches, and more.
Adding pembrolizumab before and after surgery to standard of care improved outcomes in patients with previously untreated head and neck cancer.
A recently approved first-line therapy and novel insights into optimizing treatment strategies may offer new options for esophageal cancer patients.
The test, which analyzes urine for 18 cancer-specific genes, ruled out the need for biopsy in men with elevated PSA without a digital rectal exam.
Saliva test can help identify people who are at high risk of recurrence after mouth or throat cancer treatment.
Researchers analyze whether giving immunotherapy before surgery benefits people with high-risk disease that is limited to the liver.
Patients who received Opdivo and chemotherapy had better outcomes and fewer side effects than those who had the standard-of-care therapy.
An experimental antibody helped people recover body mass lost due to cancer and treatment.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More